SLC5A2 and type 2 diabetes mellitus: Ιn a recent retrospective longitudinal study on patients with T2DM and MASLD, three-year SGLT2 inhibitor treatment significantly reduced LDL cholesterol, triglyceride, and non-HDL cholesterol, suggesting that SGLT2 inhibitors may be an ideal therapy for MASLD patients with atherosclerosis [86].